Industry Is Adapting To New Pricing Reality, Says GSK Chief Andrew Witty
This article was originally published in The Pink Sheet Daily
Andrew Witty shines a positive light on value-based pricing and adds his voice to calls for harmonized HTAs across Europe.
You may also be interested in...
EFPIA Calls On Drug Firms To Embrace Multi HTA Early Dialogue Scheme
EFPIA is calling on its members to sign up to the European Commission’s multi HTA early dialogue initiative to harmonize some significant aspects of European reimbursement.
German Reimbursement Dossiers Look Trickier After Rejection Of Eisai’s Fycompa
Eisai’s novel epilepsy drug Fycompa will have a tough time qualifying for reimbursement in Germany after the cost-effectiveness regulator IQWiG said the manufacturer did not stick to HTA guidance on comparator selection.
GSK To Downplay Europe Because of Poor Innovation Support, Focuses On Japan, U.S. Instead
GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products.